In Brief: Perkin-Elmer/PerSeptive Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer/PerSeptive Biosystems: PE expands its "proteomics" technology portfolio by completing proposed $360 mil. PerSeptive buy, a definitive stock-swap deal for which was announced on Aug. 25 ("The Gray Sheet" Sept. 1, 1997, p. 6). The combination will create a fully integrated technology platform in the field of biomedical research and drug discovery, PE claims...
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.